Era-Net (MOH): EP PerMed – Pharmacogenomic Strategies for Personalized Medicine (Pre-proposals)

The overall objectives of the JTC2025 will be to

• Support research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address one or more of the following aspects:

o    identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.

o    validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.

o    use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).

• Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.
• Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
• Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

Funding for the Israeli partner: €140,000 over 3 years.

* A short abstract and budget should be sent to the ministry of Health (MOH) prior to pre-proposal submission. Call us for clarifications and MOH abstract forms (tel. 2152, 1272).

https://www.eppermed.eu/news-events/news/ep-permed-jtc2025-pre-announcement-pharmacogenomic-strategies-for-personalised-medicine-pgxpm2025/